EGFR and head and neck cancer: It is currently being combined with trastuzumab (for HER2+ breast cancers) or with the epidermal growth factor receptor (EGFR) inhibitor cetuximab (for head and neck cancers) in phase 1 trials (NCT02627274), or with the anti-PD-L1 antibody atezolizumab in a phase 2 trial investigating advanced and/or metastatic solid tumours (NCT03386721).